Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A)

Journal of Magnetic Resonance Imaging

Volumn 14, Issue 5, 2001, Pages 595-601

  Kehagias, Dimitris T ^a   Gouliamos, Athanassios D ^a   Smyrniotis, Vassilios ^a   Vlahos, Lambros J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Contrast agents; Contrast enhancement; Liver; Liver neoplasms; Magnetic resonance

Indexed keywords

CONTRAST MEDIUM; IRON; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEART RATE; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; LIVER TUMOR; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

CONTRAST MEDIA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IRON; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES; SAFETY; SUSPENSIONS;

EID: 0034752953     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1224     Document Type: Article

References (18)

1. Focal liver diseases: Comparison of dynamic contrast-CT and T2-weighted fat suppressed, FLASH, and dynamic gadolinium-enhanced MR imaging at 1.5 T
2. Liver metastasis: Improved detection with dynamic gadolinium-enhanced MR imaging?
3. Liver metastases: Safety and efficacy of detection with superparamagnetic iron oxide in MR imaging
4. Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and the efficacy in the detection of focal hepatic lesions
5. Hepatocellular tumors: Characterization with Mn-DPDP-enhanced MR imaging
6. Multicentric doubleblind phase II clinical trial of Gd-EOB-DTPA (Eovist): Safety profile
7. A new superparamagnetic iron oxide contrast agent for magnetic resonance imaging
8. MR imaging of the liver with Resovist: Safety, efficacy, and pharmacodynamic properties
9. Superparamagentic iron oxide: Detection of focal liver lesions at high-field-strength MR imaging
10. Contrast-enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide
11. Clinical results with Resovist: A phase 2 clinical trial
12. Superparamagnetic iron oxide particles (SH U 555 A): Evaluation of efficacy in three doses for hepatic MR imaging
13. Results of a multicenter phase II clinical trial with a new susceptibility contrast medium for magnetic resonance imaging of the liver
14. Liver masses: Replacement of conventional T2-weighted spin-echo MR imaging with breathhold MR imaging
15. Hepatic lesion detection after superparamagnetic iron oxide enhancement: Comparison of five T2-weighted sequences at 1.0 T by using alternative-free response ROC analysis
16. Hepatic lesion detection and characterization: Value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging and spiral CT-ROC analysis
17. Detection of focal hepatic lesions: Comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP
18. Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagneticiron oxide Resovist versus gadolinium-DTPA in the same patient